Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer

The treatment of metastatic colorectal cancer (mCRC) has improved since the introduction of the epithelial growth factor receptor (EGFR) inhibitors as cetuximab and panitumumab. However, only patients with peculiar genomic profiles benefit from these targeting therapies. In fact, the molecular integ...

Descripción completa

Detalles Bibliográficos
Autores principales: Internò, Valeria, Tucci, Marco, Pezzicoli, Gaetano, Silvestris, Franco, Porta, Camillo, Mannavola, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546030/
https://www.ncbi.nlm.nih.gov/pubmed/33102237
http://dx.doi.org/10.3389/fonc.2020.581130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546030/
https://www.ncbi.nlm.nih.gov/pubmed/33102237
http://dx.doi.org/10.3389/fonc.2020.581130

Ejemplares similares